Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson’s Disease
Open Access
Abstract
Tavapadon, a novel oral dopamine-D1R/D5R partial agonist, has been studied in recent years for the treatment of late-stage development Parkinson’s disease (PD). Levodopa, a dopamine precursor that currently remains the gold-standard first-line therapy for PD motor symptoms, serves as a benchmark against emerging dopaminergic agents. By selectively activating D1-family receptors on direct-pathway medium neurons, Tavapadon differs in that it delivers levodopa-level motor benefit while avoiding its many D2R/D3R-mediated adverse effects. In placebo-controlled trials, Tavapadon produced clear, clinically meaningful gains in motor function and day-to-day activities, as captured by the Unified Parkinson’s Disease Rating Scale (UPDRS). Recent late-stage results have revealed that Tavapadon maintains superior UPDRS outcomes in de novo patients and, when added to levodopa, extended “ON” time periods of reliable motor control free of troublesome dyskinesia, without introducing new safety concerns. In studies, nausea, headache, and somnolence were the most frequent adverse events. Hallucinations, orthostatic hypotension, and impulse-control disorders remained comparable to placebo, reflecting minimal D2R/D3R-mediated effects. Preclinical primate studies have demonstrated levodopa-like motor rescue with markedly less dyskinesia, a pattern mirrored in clinical add-on trials. Collectively, evidence indicates that Tavapadon can match levodopa-mediated symptomatic efficacy, lower dyskinesia liability compared with levodopa or earlier full D1 receptor (D1R) agonists, and offer the convenience of once-daily dosing characteristics, which may bridge the therapeutic gap between levodopa and the current D2R/D3R agonists in PD management. In the present investigation, the emerging clinical role for Tavapadon is described, along with the mechanism of action, clinical efficacy, safety, and future directions.Keywords
This publication has 30 references indexed in Scilit:
- Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progressionJournal of Neural Transmission, 2025
- D1, not D2, dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopaEuropean Journal of Pharmacology, 2021
- D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side EffectsACS Chemical Neuroscience, 2020
- Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well ToleratedNeurology and Therapy, 2018
- MAO‐BandCOMTGenetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's DiseaseThe Journal of Clinical Pharmacology, 2018
- Levodopa-induced dyskinesia in Parkinson’s disease: still no proof? A meta-analysisJournal of Neural Transmission, 2018
- Unified Parkinson’s Disease Rating Scale2017
- Pharmacological Treatment of Parkinson DiseaseJAMA, 2014
- Pharmacokinetics and pharmacodynamics of levodopaMovement Disorders, 2008
- Induction by Dopamine D1 Receptor Agonist ABT-431 of Dyskinesia Similar to Levodopa in Patients With Parkinson DiseaseArchives of Neurology, 2001